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both radiations. Clustered DNA damage poses serious 
problems for the DNA repair and error-prone repair of DNA 
damage is associated with cancer induction. Increased 
damage complexity following exposure to mixed beams will 
suggest a higher than expected risk of cancer induction in 
modern radiotherapy. The results are consistent with the 
previous studies carried out at SU with different cell types 
and different biological assays. A synergistic interaction of 
the beam components was observed at the level of 
micronuclei, gammaH2AX foci and chromosomal aberrations. 
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Purpose or Objective: Due to its higher precision in tumor 
targeting, proton therapy could become the treatment of 
choice for head and neck cancer (HNC). Recent studies have 
shown that proton irradiation suppresses angiogenic genes 
and impairs tumor cell invasion/growth. According to the 
type of radiation, dose and fractionation, the objective of 
our study was to investigate the effect of proton (P+) versus 
photon (X) irradiations in squamous cells carcinoma (SCC), in 
respect of their proliferation, genes expression and proteins 
secretion involved in proliferation, angio/lymphangenesis, 
metastasis and anti-tumor immunity. 
 
Material and Methods: Human SCC CAL33 cells were 
irradiated 1 to 3 times and evaluated on their proliferation 
(Cell counting), genes expression (qPCR) for proliferation 
(TRF2, PLK1), angio/lymphangiogenic (VEGF-A, VEGF-C, 
VEGF-D) inflammatory (IL6, IL8, CCL2, CXCL12) and immune 
(PD-L1) responses.and protein synthesis (ELISA). 
 
Results: Cell proliferation was evaluated at 48h and at 3 
weeks after 1 irradiation and showed a significant decreased 
in both X and P+, as compared to control but more important 
in P+. After 3 irradiations, cell proliferation at 48h was 
reversed and more decreased in X vs P+. Genes expression 
was investigated at 48h after 1 and 3 irradiations at 2 and 8 
Gy. After 1 irradiation, the prevalence of gene expression 
levels associated with a poor outcome was higher in X than 
P+ at 8 Gy. After 3 irradiations, genes expression was 
increased for all but more important for P+ at 8 Gy. The 
highest expression was noted for VEGF-C (2 to 10 fold 
increase). The most frequent overexpression was noted for 
PD-L1. VEGF-C protein induction 48h after 1 and 3 
irradiations was increased in both X and P+ groups but 
decreased in high dose P+, as compared to X. 
 
Conclusion: Cell proliferation activity is in favor of P+ after a 
single irradiation, and X after multiple irradiations. Genes 
expression are overall increased in both X and P+, in a dose 
and fraction dependent manner, implicated in proliferation 
(TRF2), angio/lymphangiogenic (VEGF-A, VEGF-C, VEGF-D) 
and immune (PD-L1) responses. VEGF-C protein induction is 
increased after both X and P+ single and multiple 
irradiations, but in favor of P+, suggesting a lower 
lymphangiogenesis/metastatic dissemination immediately 
after P+. Our study sets the molecular basis for novel 
therapeutic approaches applicable to HNC in combination 
with X or P+ radiotherapy, such as angio/lymphangenic 
inhibitors or immune therapy as anti-PD1 or anti-PD-L1. 
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Purpose or Objective: The aim of this study was to appraise 
multiple properties for radiation therapy techniques applying 
flattening filter-free (3F) and flattening filter (2F) beam to 
the radiation therapy. 
 
Material and Methods: Alderson rando phantom was scanned 
for computed tomography images. Treatment plans for 
intensity modulated radiation therapy (IMRT), volumetric 
modulated arc therapy (VMAT) and stereotactic body 
radiation therapy(SBRT) with 3F and 2F beam were designed 
for prostate cancer. To evaluate the differences between the 
3F and 2F beam, total monitor units (MUs), beam on time 
(BOT) and gantry rotation time (GRT) were evaluated and 
measured with TrueBeam™ STx and Surveillance And 
Measurement (SAM) 940 detector was used for photoneutron 
emitted by using 3F and 2F. 
 
Results: In using 3F beam, total MUs in IMRT plan increased 
the highest up to 34.0% and in the test of BOT and GRT, the 
values in SBRT plan by 3F beam decreased the lowest 39.8, 
38.6% respectively. The values of photoneutron occurrence in 
SBRT plan using 3F beam decreased the lowest 48.1%. 
 
Conclusion: According as the results, total MUs increased by 
using 3F beam than 2F beam in all treatment plans but BOT, 
GRT and photoneutron decreased by using 3F beam. From 
above the results, using 3F beam can have an effect on 
decreasing intra-fraction setup error and risk of radiation-
induced secondary malignancy. 
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Purpose or Objective: Patients with Small-Cell Lung Cancer 
(SCLC) have a high risk of developing brain metastasis. 
Prophylactic Cranial Irradiation (PCI), is applied to SCLC 
patients that response to chemotherapy. It is well known that 
PCI is associated with an increase in median overall survival. 
There are approximately 84 incidences per year in central 
region DK. Radiotherapy (RT) to this group of patients is 
conventionally performed using opposed MLC defined static 
fields. However, treatment planning can be time consuming. 
The aim of this study is to evaluate time-effectiveness, by 
changing the treatment technique from conventional to IMRT 
based treatment planning of PCI patients. 
 
Material and Methods: This retrospective study included 
twenty SCLC patients, all treated with conventional planned 
PCI. Each patient received 25 Gray in 10 fractions. An IMRT 
template was made (Eclipse Version 11.0, Varian Medical 
Systems, Palo Alto, CA) and for each patient an IMRT plan 
was generated by one IMRT optimization. One intermediate 
dose calculation was performed during optimization before 
the final dose calculation. The contoured structures used for 
comparison between IMRT and conventional planning were: 
ITV, PTV and left/right lens. The plans were evaluated and 
compared on; max- and minimum doses, the mean/maximum 
doses to the lenses, and the homogeneity index (HI). The HI 
was defined by D5%/D95%. Quality assurance of the IMRT 
plans was performed by recording Portal Dosimetry Images 
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(PDI) for ten of the plans, and by independent dose 
calculation checks using RadCalc (RadCalc Version 6.2, 
LifeLine Software Inc, Tyler, USA). 
 
Results: The observed differences between the conventional 
and the IMRT plans were limited. In average the maximum 
dose was 0.3 percentage points (pp) lower for IMRT than for 
conventional plans. The ITV coverage was better for the IMRT 
plans, with an average ITV minimum dose of 95.9 % compared 
to 94.1% (+1.8 pp). However, the PTV coverage was slightly 
worse for the IMRT plans, a decrease of 0.4 pp in V95%. The 
only relevant organs at risk are the lenses, were the 
maximum dose on average were lowered 0.3 Gray and the 
mean dose on average was lowered 0.1 Gray. The average HI 
for the IMRT plans was 4.0 while 5.1 for the conventional 
plans. The 10 PDI measurements were all accepted with a 
reference gamma index value of 5% dose agreement within 3 
mm distance to agreement, and no further measurements 
were performed. Independent dose calculation checks were 
performed for QA. The time spend on treatment planning was 
approximately 20 minutes for IMRT plans and could easily be 
up to 3 hours when using the conventional technique. 
 
 
Conclusion: It was possible to significantly reduce the time 
spend on dose planning by changing the treatment technique 
from conventional to IMRT for PCI patients while attaining 
comparable dosimetric quality of the treatment plans. 
Furthermore, both the treatment time and the time spend on 
quality assurances are comparable for the two techniques. 
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Purpose or Objective: To illustrate the technique and 
outcome of stereotactic body radiation therapy (SBRT) using 
Tomotherapy for refractory bone pain from metastatic 
disease. Tomotherapy SBRT planning parameters and 
dosimetric evaluation are outlined. 
 
Material and Methods: In 2013, a 70 year old female patient 
presented with metastatic non-small cell lung carcinoma, 
following resection of lung primary in 2012. CT and MRI 
confirmed a lytic lesion on right of sacrum. Patient’s sacrum 
initially treated with 30Gy/10Fx. Pain recurred 2 months post 
RT and managed by palliative care. 6 months post RT patient 
returned for consideration of re-treatment. Pain was 
refractory to everything apart from 15mg of oxycodone every 
hour. RO discussed the patient and risks of re-irradiation 
within the multidisciplinary setting. The consensus was to 
offer the patient SBRT, 24Gy in 3 fractions to the sacrum.  
Helical Tomotherapy was used to plan and treat patient. The 
irregular PTV volume was 201.12cm3. Dose volume 
constraints included: colon (0.035cc<18.4Gy, 20cc<14.3Gy), 
sacral plexus (0.035cc<11Gy, 5cc<7Gy), cauda equina 
(0.035cc<16Gy, 5cc<14Gy), and skin (0.035cc<26Gy, 
10cc<23Gy). No hotspots were to be located over the nerve 
roots. 
 
Results: Tomotherapy planning parameters included field 
width of 2.5cm, pitch of 0.2 and a modulation factor of 1.5. 
Beam on time was 400.3 seconds. PTV coverage statistics 
were D99 = 22.5Gy (93.75%), V95 = 98.57%, VTD = 90.53%, 
Median = 25.37Gy (105.71%), D1 = 27.8Gy (115.83%). OAR 
dose included colon 0.035cc = 8.1Gy, 20cc = 6.8Gy; sacral 
plexus 0.035cc = 27.3Gy, 5cc = 25.3Gy; cauda equina 0.035 = 
26.2Gy, 5cc = 21Gy; skin 0.035cc = 15.4Gy, 10cc = 12.3Gy. 
The conformity index statistics were R100% = 0.97, V105% 
outside PTV = 2cc, R50% = 4.21, Dmax > 2cm from PTV = 
16.45Gy (68.5%).  
One week post SBRT, patient’s pain stable and mobility 
improving. Whole body bone scan 2 months post SBRT showed 
decreased activity and size of sacral lesion. 4 months post 
SBRT patient returned with significant left sacral pain with 
concern of further metastatic disease. PET confirmed no 
uptake in left sacrum. Pain associated with insufficiency 
fracture with cause unknown, SBRT or bone metastasis likely 
contributors. 5 months post SBRT patient improved 
dramatically, completely ambulant with PET/CT showing no 
evidence of recurrence/metastatic disease. 13 months post 
SBRT, patient remains asymptomatic, CT shows no evidence 
of metastatic disease. 
 
Conclusion: This case study illustrates how the use SBRT can 
result in pain control for patients with refractory metastatic 
bone pain where there may be no other options available 
apart from palliative care, even in cases where the 
treatment volume is relatively large. This data is also 
informative since the patient shows no definite evidence of 
metastatic disease. Further studies could lead to improved 
therapies for the control of metastatic bone pain. 
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Purpose or Objective: Proton therapy cancer treatment 
offer potential clinical advantages compared with photon 
radiation therapy for many cancer sites. However, the 
treatment cost with proton is much higher than with 
conventional radiation. The objective of this study is to 
discuss how to improve a procedure, already described by 
others worldwide, to provide quantitative clues to select the 
patient for proton treatment instead of photon. 
 
Material and Methods: The respective medical and clinical 
benefits of proton and photon therapy are assessed by in 
silico comparison following four successive steps. First, the 
dosimetric analysis is made using parameters derived from 
dose volume histogram (DVH) for target volume and organs at 
risks. Second, the DVHs are exported from TPS to calculate 
TCP and mostly NTCP radiobiological indexes. In the third 
step, a statistical comparison is done using non-parametric 
test to calculate p-value, then bootstrap method is used to 
estimate the confidence intervals including the lower and 
upper limit of agreements. Then the correlation between 
data from proton and photon treatment planning is assessed 
using Spearman’s rank test. Finally, the cost-effectiveness 
and quality adjusted life years (QALYs) can be used to 
measures the outcome of the therapy and check if the 
therapeutic gain of proton therapy worth the increased 
expenses of it versus photon. 
 
Results: The results with in silico data can be taken into 
account to make a proposal of a decisional procedure. The 
dosimetric and radiobiological analysis can be used to check 
the medical benefit with either proton or photon. The 
statistical tests allow to check if the dosimetric or 
radiobiological benefits for a specific patient can be included 
in the confidence interval of agreement of a representative 
population, the most homogenous possible. A Markov model 
can be used to simulate the life of patients treated with 
proton / photon radiation. The virtual evaluation may 
indicate for which cancer sites proton therapy could be more 
cost-effective than photon therapy. 
 
Conclusion: The introduction of model based clinical trials 
with the possibility of individual assessment is a coming 
approach well adapted to the fast improvement of medical 
technology. The presently rising offer of proton therapy is a 
good example. The QALY concept based on objective 
dosimetric and clinical expected / modelized outcome may 
be a valuable response to this new challenge. However, large 
